Skip to content
For laboratory research use only · Not for human or veterinary use · Qualified buyers only
Peptides

What Are Bioregulator Peptides? Short-Peptide Class and Documentation

A research-use class note on short bioregulator peptides, with published name-to-sequence mapping for KE, KED, EDR, and AEDG and lot-documentation limits.

What Are Bioregulator Peptides? Short-Peptide Class and Documentation

Bioregulator peptides are very short sequences investigated in gene-expression, tissue-specific signaling, and aging-model research. The original overview of this page asks three questions: how short peptide sequences are classified, why tissue context matters in experimental interpretation, and sequence confirmation and lot-level documentation.

Editorial review: 17 November 2026. Prepared by Velnacor Research Desk for research-use communication only. Published findings below are attributed to the cited papers. They are not claims about a Velnacor lot and are not instructions for use in people or animals.

How short peptide sequences are classified

Khavinson, Popovich, Linkova, Mironova, and Ilina published a systematic review of peptide regulation of gene expression and explicitly mapped several short-peptide names to sequences: KE (Vilon), KED (Vesugen), EDR (Pinealon), and AEDG (Epitalon) (Khavinson et al., 2021, Molecules). That mapping is used here as a class-and-identity note. “Bioregulator” is a literature class name, not a single specification. Each short sequence still needs its own identity file. Companion identity notes are at What Is Vilon?, What Is Vesugen?, and What Is Pinealon?.

Why tissue context matters

The 2021 systematic review summarizes prior reports in the language of gene-expression regulation and related laboratory models (Khavinson et al., 2021, Molecules). That is the authors’ synthesis of earlier literature. It is not, by itself, an established clinical claim, and it does not transfer a finding from one short peptide or one tissue model to another. Tissue, cell type, and endpoint should be named in the protocol. Findings reported for KED or EDR in a mouse model, for example, should not be filed as if they were findings for KE, or as if they were a human outcome. See the individual pages for the attributed papers used on those sequences.

Sequence confirmation and lot-level documentation

Short peptides require methods suited to low mass: sequence or compositional identity, purity, content, and lot matching. A class name on a quotation is not a substitute for those records. What Is a Peptide COA?, How to Read a Peptide COA, HPLC vs Mass Spectrometry for Peptide Lot Review, and lot traceability apply independently to each line item.

Velnacor’s current research-material catalog listing used for this draft includes Epithalon and Thymalin (internal product records). Vilon, Vesugen, and Pinealon were not found as standalone published catalog items in that listing. There is not a standalone public landing page for every catalog name; use the product directory and the COA Library, then confirm each name, sequence, and current-lot documents in the inquiry. For packing at supply scale, see wholesale peptides.

Short-peptide class pages are a frequent source of name confusion. KE, KED, EDR, and AEDG are different sequences. Thymalin, where it appears in a catalog, is a further distinct material and should not be filed as if it were one of those tetrapeptides or dipeptides. Gene-expression or “geroprotection” language in the systematic review is the authors’ framing of prior reports; it is not adopted here as an established clinical claim, and it is not a reason to skip sequence confirmation on each lot.

Selected published literature

  1. Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide regulation of gene expression: a systematic review. Molecules. 2021;26(22):7053. doi:10.3390/molecules26227053. PubMed 34834147. Open access: PMC8619776. Systematic review; cited for name-to-sequence mapping and for the authors’ summary of prior reports, not as a use instruction or as a clinical claim.

Sourcing notes for qualified buyers

Velnacor’s stated supply terms for qualified research and business buyers include: every batch is third-party tested; orders usually ship within 24 hours, subject to stock, documentation review, and destination; trial orders can start from one box of ten vials; parcels lost or damaged in transit are eligible for free reshipment or a refund; and neutral packaging is available when required. Velnacor operates its own production base and has a long-standing supply-chain business.

Those points describe documentation and fulfillment. They do not describe a laboratory or biological outcome. For an order-specific review, send the material name, specification, box quantity, and destination through the inquiry list.

Research-use notice. All Velnacor products are intended strictly for laboratory research use only. They are not drugs, supplements, or food, and are not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Purchasers must be qualified researchers. This article is educational content for laboratory and business readers. It does not provide dosing, reconstitution, administration, diagnostic, or treatment guidance.

My inquiry listNo products added yet0